Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients
- Conditions
- Pulmonary Disease, Chronic ObstructiveMajor Depression
- Interventions
- Behavioral: Enhanced CareBehavioral: Treatment Adherence Intervention
- Registration Number
- NCT00151372
- Lead Sponsor
- Weill Medical College of Cornell University
- Brief Summary
Approximately 20% of patients with chronic obstructive pulmonary disease (COPD) have major depression, a condition that contributes to suffering but also to poor treatment adherence leading to increased disability and morbidity. This study investigates the effectiveness of a care management intervention aimed at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability at a 28-week follow-up period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 141
- Chronic obstructive pulmonary disease by American Thoracic Society criteria
- Major depression by DSM-IV criteria
- 17-item Hamilton score >14
- English speaking
- Inability to give informed consent
- MiniMental score <24
- Aphasia
- Nursing home placement after discharge
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Enhanced Care Enhanced Care In the Enhanced Care group, physicians providing aftercare will be informed in writing of the patients' diagnosis but will receive no clinical instructions by the research team. Treatment Adherence Intervention Treatment Adherence Intervention In the Treatment Adherence Intervention group, a study therapist regularly meets with subjects in order to identify obstacles to depression and chronic obstructive pulmonary disease treatment adherence and to help the participant overcome those obstacles.
- Primary Outcome Measures
Name Time Method Composite Antidepressant Score Scale (CAD) 28 Weeks The Composite Antidepressant Score scale (CAD) describes the adequacy of an antidepressant's dosage. Scores range from 0-4 with 0, 1, and 2 signifying subthreshold or non-adequate therapeutic dosages while 3 and 4 signify a therapeutic/adequate dosage. The best value is 4 while the worst value is 0.
- Secondary Outcome Measures
Name Time Method Hamilton Depression Rating Scale 28 Weeks The 17-item Hamilton Depression Rating Scale (HDRS) measures the severity of a depressive episode: the higher the score, the more severe the depression. The Best value is 0 and the Worst value is 52.
Trial Locations
- Locations (3)
Helen Hayes Hospital
🇺🇸West Haverstraw, New York, United States
Weill Medical College of Cornell University
🇺🇸White Plains, New York, United States
Burke Rehabilitation Hospital
🇺🇸White Plains, New York, United States